Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
2024年8月29日 - 5:05AM
Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage
company developing transformational treatments for patients with
serious metabolic diseases marked by high unmet medical need, today
announced that management will present at the Morgan Stanley 22nd
Annual Global Healthcare Conference on Wednesday, September 4,
2024, at 7:45 a.m. E.T. in New York, NY.
A live webcast of the Company presentation will be available
through the investor relations section of the Company's website
at www.akerotx.com. Following the live webcast, an archived
replay will be available on the Company's website.
About Akero TherapeuticsAkero Therapeutics is a
clinical-stage company developing transformational treatments for
patients with serious metabolic diseases marked by high unmet
medical need, including MASH. Akero's lead product candidate, EFX,
is currently being evaluated in the ongoing SYMMETRY study, a
96-week Phase 2b clinical trial in patients with compensated
cirrhosis due to MASH (F4 fibrosis), as well as three ongoing Phase
3 clinical trials in patients with pre-cirrhotic MASH or
compensated cirrhosis due to MASH: SYNCHRONY Histology, SYNCHRONY
Real-World, and SYNCHRONY Outcomes. The SYNCHRONY program builds on
the results of two Phase 2b clinical trials, the HARMONY study in
patients with pre-cirrhotic MASH (F2-F3) and the SYMMETRY study in
patients with compensated cirrhosis due to MASH (F4). Akero is
headquartered in South San Francisco. Visit us
at akerotx.com and follow us
on LinkedIn and X for more information.
Investor Contact:Christina TartagliaPrecision
AQ212.362.1200christina.tartaglia@precisionaq.com
Media Contact:Peg
Rusconi617.910.6217peg.rusconi@deerfieldgroup.com
Akero Therapeutics (NASDAQ:AKRO)
過去 株価チャート
から 9 2024 まで 10 2024
Akero Therapeutics (NASDAQ:AKRO)
過去 株価チャート
から 10 2023 まで 10 2024